Evekeo

Narcolepsy, Depression, Attention Deficit Hyperactivity Disorder + 1 more

Treatment

2 FDA approvals

20 Active Studies for Evekeo

What is Evekeo

Amphetamine/Dextroamphetamine

The Generic name of this drug

Treatment Summary

Amphetamine is a type of drug that has been around for over 100 years. It was once used to treat a variety of conditions, but now it is only used in limited cases. Amphetamine has the chemical formula alpha-methylphenethylamine and was originally developed in 1910 and synthesized by 1927. It was used to reduce drug-induced anesthesia, promote wakefulness, and cause arousal and insomnia. During World War II, it was used to help keep soldiers awake. However, after the war ended, excess supplies of amphetamine ended up in the black market, leading to its misuse and illicit abuse.

Adderall

is the brand name

image of different drug pills on a surface

Evekeo Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Adderall

Amphetamine/Dextroamphetamine

1996

507

Approved as Treatment by the FDA

Amphetamine/Dextroamphetamine, also known as Adderall, is approved by the FDA for 2 uses such as Narcolepsy and Attention Deficit Hyperactivity Disorder .

Narcolepsy

Attention Deficit Hyperactivity Disorder

Used to treat Attention Deficit Hyperactivity Disorder (ADHD) in combination with Dextroamphetamine

Effectiveness

How Evekeo Affects Patients

Amphetamine increases the amount of two important brain chemicals, noradrenaline and dopamine. It has been used to improve intelligence test scores, and has been shown to help people with ADHD improve their school performance, behavior, and demeanor. It is usually used in a 3:1 ratio of two forms of the drug. While it is sometimes used to treat depression and anxiety, amphetamine use can also lead to a paranoid state and should not be misused.

How Evekeo works in the body

Amphetamine works by mimicking the structure and action of neurotransmitters. It competes with the neurotransmitters to be taken up by nerve terminals, and is then stored in vesicles. It is then released into the synapse where it blocks the reuptake of dopamine, noradrenaline, and serotonin. Lastly, it inhibits an enzyme responsible for breaking down excess neurotransmitters.

When to interrupt dosage

The suggested dose of Evekeo relies upon the diagnosed affliction, including Disease, Chronic Pain and Attention Deficit Hyperactivity Disorder. The measure of dosage can be found in the indicated table, based on the technique of delivery (e.g. Oral or Tablet - Oral).

Condition

Dosage

Administration

Attention Deficit Hyperactivity Disorder

, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg

, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral

Chronic Pain

, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg

, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral

Narcolepsy

, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg

, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral

Depression

, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg

, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral

Warnings

Evekeo Contraindications

Condition

Risk Level

Notes

Agitation

Do Not Combine

advanced arteriosclerosis

Do Not Combine

Drug abuse

Do Not Combine

Hyperthyroidism

Do Not Combine

Hypertensive disease

Do Not Combine

symptomatic cardiovascular disease

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Amphetamine/Dextroamphetamine may interact with Pulse Frequency

There are 20 known major drug interactions with Evekeo.

Common Evekeo Drug Interactions

Drug Name

Risk Level

Description

Clonidine

Major

The metabolism of Clonidine can be decreased when combined with Amphetamine.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Amphetamine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Amphetamine.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Amphetamine.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Amphetamine.

Evekeo Toxicity & Overdose Risk

The mean lethal dose of amphetamine is 6.4 mg/l. Symptoms of an overdose include high body temperature, decreased breathing, seizures, acidity of the blood, kidney failure, liver damage, and loss of consciousness. Other effects may include agitation, aggressive behavior, headache, hallucinations, irregular heartbeat, heart muscle damage, abdominal pain, vomiting, diarrhea, cramps, lack of appetite, and bleeding in the digestive tract. In animal studies, amphetamine has not been linked to cancer, genetic mutation, or fertility problems.

image of a doctor in a lab doing drug, clinical research

Evekeo Novel Uses: Which Conditions Have a Clinical Trial Featuring Evekeo?

710 active experiments are being conducted to investigate the potential of Evekeo to combat Depression, Disease and Narcolepsy.

Condition

Clinical Trials

Trial Phases

Narcolepsy

2 Actively Recruiting

Not Applicable, Phase 1

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Chronic Pain

0 Actively Recruiting

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Evekeo Reviews: What are patients saying about Evekeo?

5

Patient Review

6/24/2015

Evekeo for Attention Deficit Disorder with Hyperactivity

I've tried so many other treatments and they either don't work or I feel awful on them. This one works quickly and lasts about 7 hours for me. I've been on it for two weeks and haven't had any side effects really. I also received a free trial and I did not have to pay anything for a 60 tablet supply. My doc also gave me a copay card to use after that will really keep the cost down. Safe to say I'll be sticking with Evekeo!

5

Patient Review

8/3/2015

Evekeo for Attention Deficit Disorder with Hyperactivity

This is my first time taking medication for ADHD, and I think it's helping. I started with a low dose of 5mg twice a day, and increased it to 10mg after a week. I felt some side effects at the lower dose, but they were manageable. So far so good, and I plan on continuing the treatment for now.

5

Patient Review

10/2/2015

Evekeo for Attention Deficit Disorder with Hyperactivity

I found this treatment to be much better than generic adderall. It lasts longer and helped me focus more. The free trial is also a nice bonus so you can test it out before committing to it.

5

Patient Review

5/17/2016

Evekeo for Attention Deficit Disorder with Hyperactivity

After trying other drugs, my doctor recommended this one. It helps me focus without any terrible side effects, which I'm grateful for.

5

Patient Review

6/23/2018

Evekeo for Weight Loss Management for an Obese Person

In just four months, I've dropped 40 pounds. Evekeo makes it much easier to diet and exercise by suppressing my appetite and giving me energy boosts. It's been wonderful for me; the only downside is that sometimes my heart races, even though my blood pressure seems fine.

5

Patient Review

4/20/2018

Evekeo for Attention Deficit Disorder with Hyperactivity

I appreciate the fact that I was able to get a free trial from my doctor. My son's ADHD is much better managed now and he's doing great in school again. The flexible dosing is really helpful, and it only costs me $15 per month through our local pharmacy copay program.

5

Patient Review

5/4/2018

Evekeo for Attention Deficit Disorder with Hyperactivity

I wasn't able to focus before taking this medication, and it was really disrupting my life. Evekeo has been a lifesaver for me, 10mg is the perfect amount to help me get through my day without feeling jittery or out of control.

4.3

Patient Review

12/8/2015

Evekeo for Attention Deficit Disorder with Hyperactivity

I've tried four different medications for my ADD and this one by far is the best. I just wish they had higher strengths available; 15mg twice daily works well for me, but I have to break the tablet in half which is annoying. There are no side effects that I've noticed and it really helps with my attention deficit disorder.

4.3

Patient Review

8/31/2015

Evekeo for Attention Deficit Disorder with Hyperactivity

I've been using this for two weeks and it's definitely better than Adderall. The only downside is that I turn into a bit of a jerk at the end of the day, but smoking some weed takes care of that.

3

Patient Review

5/12/2016

Evekeo for Attention Deficit Disorder with Hyperactivity

Recently switched to Evekeo, but it was difficult to find a pharmacy that had it in stock. Additionally, my insurance didn't cover it. The coupon from the doctor helped offset some of the cost, but I think I'm going to switch back to my old medication (Adderall Tablet).

1.3

Patient Review

6/25/2018

Evekeo for Attention Deficit Disorder with Hyperactivity

I found this treatment to be ineffective and actually quite counterproductive. It made me more sleepy and irritable, rather than helping my ADHD symptoms.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about evekeo

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the generic for Evekeo?

"Evekeo is a medication used to treat attention deficit hyperactivity disorder (ADHD). It is a short-acting stimulant that is taken orally. It is available in tablet and capsule form."

Answered by AI

How does Evekeo make you feel?

"It's common for people to abuse Evekeo because it affects dopamine levels in the brain and can create a feeling of euphoria. When people abuse large doses of Evekeo, this feeling is even more intense."

Answered by AI

What is the difference between Adderall and Evekeo?

"Evekeo is an ADHD stimulant medication that was approved by the FDA in 2014. It is an amphetamine sulfate that is similar to Adderall, but it has a different composition. Adderall is 75 percent dextroamphetamine and 25 percent levoamphetamine, whereas Evekeo is an even 50 percent of each."

Answered by AI

What is Evekeo used for?

"Amphetamine is a medication used to treat attention deficit hyperactivity disorder (ADHD). It works by changing the amounts of certain natural substances in the brain. Amphetamine belongs to a class of drugs known as stimulants."

Answered by AI

Clinical Trials for Evekeo

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Have you considered Evekeo clinical trials?

We made a collection of clinical trials featuring Evekeo, we think they might fit your search criteria.
Go to Trials
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Have you considered Evekeo clinical trials?

We made a collection of clinical trials featuring Evekeo, we think they might fit your search criteria.
Go to Trials
Image of Lincoln Middle School in Cottage Grove, United States.

Behavioral Interventions for Depression in Students

Any Age
All Sexes
Cottage Grove, OR

The goal of this clinical trial is to learn if two behavioral interventions work to reduce office disciplinary referrals, improve attendance, and reduce depression and anxiety in 7th grade students. This project combines two evidence-based programs-the Inclusive Skill-building Learning Approach (ISLA) for school-wide discipline reform and the Family Check-Up Online (FCU-O) for family-centered support-in an adaptive design to examine the unique and additive effects of these interventions on these child behavior outcomes. The main questions it will answer are: 1. What is the relative efficacy of ISLA vs. School-as-Usual? 2. What is the optimal sequencing of these interventions? 3. Which overall sequence of intervention strategies was most effective? Researchers will compare 6 combinations of these interventions to see which combination and sequencing provides the best student outcomes. School personnel participating in the project will be trained to implement the two interventions at their school. They will answer surveys in the fall, winter, and spring of their year of participation. Parent and Youth participants will complete surveys at baseline and then again 6 months and 12 months later.

Waitlist Available
Has No Placebo

Lincoln Middle School (+12 Sites)

Beth Stormshak, PhD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Evekeo clinical trials?

We made a collection of clinical trials featuring Evekeo, we think they might fit your search criteria.
Go to Trials